Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study
- 1 October 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 13 (10), 1250-1255
- https://doi.org/10.1002/ibd.20187
Abstract
The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. Eighteen patients with active pouchitis were randomized to receive oral rifaximin 400 mg or placebo 3 times daily for 4 weeks. Active pouchitis was defined as a total Pouchitis Disease Activity Index (PDAI) score = 7 points. Clinical remission was defined as a PDAI score <7 points and a decrease in the baseline PDAI score = 3 points. The primary analysis was clinical remission at week 4. Eight patients were randomized to rifaximin and 10 patients were randomized to placebo. One patient in the placebo group did not have a post-baseline efficacy evaluation and was excluded from the efficacy analysis. Two of 8 patients (25%) treated with rifaximin were in clinical remission at week 4 compared to 0 of 9 patients (0%) treated with placebo (P = 0.2059). None of 8 patients in the rifaximin group withdrew from the trial prior to week 4. Two of 9 patients in the placebo group withdrew prior to week 4 due to lack of efficacy and were categorized as treatment failures. Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.Keywords
This publication has 14 references indexed in Scilit:
- Diagnosis and management of pouchitis1 1Abbreviations used in this paper: EIM, extraintestinal manifestations; FAP, familial adenomatous polyposis; IL, interleukin; IPAA, ileal pouch anal anastomosis; pANCA, serum antineutrophil cytoplasmic antibody-perinuclear staining pattern; PAS, Pouchitis Activity Score; PDAI, Pouchitis Disease Activity Index; PSC, primary sclerosing cholangitis; QOL, quality of life; SCFA, small chain fatty acids.Gastroenterology, 2003
- Therapy of Travelers' Diarrhea With Rifaximin on Various ContinentsAmerican Journal Of Gastroenterology, 2003
- Budesonide enema in pouchitis—a double‐blind, double‐dummy, controlled trialAlimentary Pharmacology & Therapeutics, 2002
- A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute PouchitisInflammatory Bowel Diseases, 2001
- Pouchitis following pelvic pouch operation for ulcerative colitisDiseases of the Colon & Rectum, 1996
- Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.Gut, 1996
- RifaximinDrugs, 1995
- Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitisDigestive Diseases and Sciences, 1994
- Incidence and Characteristics of Pouchitis in the Kock Continent Ileostomy and the Pelvic PouchScandinavian Journal of Gastroenterology, 1993
- Ileal ecology after pouch-anal anastomosis or ileostomyGastroenterology, 1989